Press releases

- Second quarter Orenitram® revenue growth of 40% year-over-year- INCREASE sNDA submitted to FDA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 29, 2020 /PRNewswire/ -- United Therapeutics...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 23, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the United States Patent and Trademark Office issued a new patent on July...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2020 financial results before the...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvaso® (treprostinil) Inhalation...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 5, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. District Court for the District...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United...

- First quarter Orenitram® net revenue growth of 18% year-over-year - Major milestones such as the INCREASE filing and Remunity™ Pump launch remain on track despite the COVID-19 pandemic - United...

- Orenitram demonstrated improvement in hemodynamic parameters and risk status, important indicators of long-term outcomes in PAH patients, in presentations at recent scientific conferences - Separately, total...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2020 financial results before the...

~ Full year net revenue growth of 3% excluding Adcirca® ~ ~ Company expects 2020 full year net revenue growth ~ ~ INCREASE study of Tyvaso® in PH-ILD meets primary and secondary endpoints ~~ Remunity™...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United...